Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL-15293 in KRAS G12C Mutated Advanced Solid Tumors
NCT05119933Phase 2Unknown
- Sponsor
- Yingli Pharma
- Start
- Nov 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of YL-15293 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Yingli Pharma. Primary endpoint: Overall Response Rate at 2 years. Status: unknown.
02
Drugs
YL-15293
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05119933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05119933.